Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plozasiran in Chinese adults with Familial Chylomicronemia Syndrome
NCT05902598Phase 3Completed
- Sponsor
- Visirna Therapeutics
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of plozasiran in familial chylomicronemia syndrome (FCS), sponsored by Visirna Therapeutics. Primary endpoint: Percent Change From Baseline in Fasting Serum Triglyceride at Month 10. Started Jul 2023; status: completed.
02
Drugs
plozasiran
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT05902598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902598.